Pharmaceutical R&D is at an inflection point, witnessing a profound transformation that challenges the historical dichotomy between small and large…
Read More
Lilly Emerges as Top Pharma Company by Revenue in FY2025, Fueled by Mounjaro and Zepbound’s $36.5 Billion Success
Eli Lilly and Company has officially concluded its fiscal year 2025 as the world’s leading pharmaceutical enterprise by revenue, a…
Read More
Revolutionary Eye Drops Derived from Pig Semen Show Promise for Non-Invasive Ocular Cancer Treatment
A groundbreaking study published in Science Advances reveals that researchers in China have successfully engineered eye drops utilizing exosomes derived…
Read More
The New York Times spotlighted MEDVi. The FDA had already warned the self-proclaimed ‘fastest growing company in history.’
A burgeoning telehealth startup, MEDVi, heralded by The New York Times as a prime example of an AI-powered venture reaching…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025
The pharmaceutical industry’s financial landscape is undergoing a significant transformation, marked by the continued brand dominance of Merck’s Keytruda (pembrolizumab)…
Read More
Pharma 50: The 50 Best-Selling Drugs of FY2025
The fiscal year 2025 concluded with a dramatic reshaping of the pharmaceutical industry’s top echelons, marked by intense competition at…
Read More
Eli Lilly Ascends to Pharma’s Top Revenue Spot Amidst Oral GLP-1 Approval, Yet Wall Street Remains Unconvinced.
Eli Lilly and Company, a venerable titan in the pharmaceutical industry, has achieved an unprecedented milestone, claiming the top spot…
Read More
Rethinking Evidence Generation for Ultra-Rare Diseases
Developing effective treatments for ultra-rare diseases has long presented a profound paradox for the biopharmaceutical industry and regulatory bodies. While…
Read More
A Billion-Dollar Telehealth Empire Built on Regulatory Cracks: The Medvi Controversy
Medvi, a telehealth company recently profiled by The New York Times as an AI-powered success story, is projected by its…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
In the wake of The New York Times’ April 2 profile, which painted MEDVi CEO Matthew Gallagher as a "vibe-coded…
Read More
